Four months ago, Rigel Pharmaceuticals spent just $2 million—plus ponying up another $233 million in potential milestones—to acquire Forma Therapeutics’ leukemia drug Rezlidhia. On Thursday, Rigel got ...
Zacks Investment Research on MSN
Will Tavalisse continue to drive Rigel Pharmaceuticals' growth in 2026?
Rigel Pharmaceuticals RIGL had an encouraging year in 2025. The company is yet to report its fourth-quarter and full-year ...
Rigel Pharmaceuticals has seen its consensus analyst price target rise from $38.33 to $45.40, indicating heightened optimism about the company’s financial trajectory. This optimism coincides with a ...
Rigel Pharmaceuticals climbs 59% in a year as Tavalisse anchors growth, oncology gains traction and 2026 guidance points to ...
(RTTNews) - Shares of Rigel Pharmaceuticals, Inc. (RIGL) are slipping over 11% in extended session on Monday after the company said it has received guidance from the U.S. Food and Drug ...
Rigel Pharmaceuticals RIGL is scheduled to report third-quarter 2025 results on Nov. 4, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $61.6 ...
SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced that it has received guidance from the U.S. Food and Drug Administration (FDA)'s review of ...
CEO Raul Rodriguez highlighted "year-over-year net product sales growth of 68%" and total revenue of $53.3 million for Q1 2025. He noted that Rigel achieved $11.4 million in net income for the quarter ...
Shares of Rigel Pharmaceuticals (NASDAQ: RIGL) jumped 20.9% in August, according to data provided by S&P Global Market Intelligence as investors in the biotech become more comfortable with the ...
*NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. Total costs and expenses were $40 ...
Rigel’s IRAK1/4 inhibitor, R289, has shown promising results in a Phase 1b trial for relapsed/refractory lower-risk myelodysplastic syndrome (LR-MDS). The initial data presented at ASH 2024 ...
Here's why this stock's big run-up in recent months could be just the beginning. A new collaboration deal with a big pharmaceutical company isn't the only reason to keep an eye on this often ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results